BRIEF-Alector To Discontinue Phase 2 Trial Of Nivisnebart

Alector

Alector

ALEC

0.00

April 29 (Reuters) - Alector Inc ALEC.O:

  • ALECTOR TO DISCONTINUE PHASE 2 PROGRESS-AD TRIAL OF NIVISNEBART (AL101/GSK4527226) IN EARLY ALZHEIMER’S DISEASE FOLLOWING INTERIM FUTILITY ANALYSIS

  • ALECTOR INC - TARGETS IND APPLICATION FOR AL050 ENZYME REPLACEMENT THERAPY IN 2027

  • ALECTOR INC - TARGETS IND SUBMISSION FOR AL037/AL137 ANTI-AMYLOID BETA ANTIBODY IN Q1 2027

Source text: ID:nGNX1PZXT5

Further company coverage: ALEC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.